296 related articles for article (PubMed ID: 28090679)
1. Effect of prucalopride on intestinal gas tolerance in patients with functional bowel disorders and constipation.
Malagelada C; Nieto A; Mendez S; Accarino A; Santos J; Malagelada JR; Azpiroz F
J Gastroenterol Hepatol; 2017 Aug; 32(8):1457-1462. PubMed ID: 28090679
[TBL] [Abstract][Full Text] [Related]
2. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation.
Sloots CE; Poen AC; Kerstens R; Stevens M; De Pauw M; Van Oene JC; Meuwissen SG; Felt-Bersma RJ
Aliment Pharmacol Ther; 2002 Apr; 16(4):759-67. PubMed ID: 11929394
[TBL] [Abstract][Full Text] [Related]
3. Prucalopride, a systemic enterokinetic, for the treatment of constipation.
Emmanuel AV; Roy AJ; Nicholls TJ; Kamm MA
Aliment Pharmacol Ther; 2002 Jul; 16(7):1347-56. PubMed ID: 12144586
[TBL] [Abstract][Full Text] [Related]
4. Effect of selective CCK1 receptor antagonism on accommodation and tolerance of intestinal gas in functional gut disorders.
Lobo B; Serra J; D'Amato M; Rovati L; Malagelada JR; Santos J; Azpiroz F
J Gastroenterol Hepatol; 2016 Feb; 31(2):288-93. PubMed ID: 26416485
[TBL] [Abstract][Full Text] [Related]
5. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
[TBL] [Abstract][Full Text] [Related]
6. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial.
Coremans G; Kerstens R; De Pauw M; Stevens M
Digestion; 2003; 67(1-2):82-9. PubMed ID: 12743445
[TBL] [Abstract][Full Text] [Related]
7. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
Gale JD
Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury.
Krogh K; Jensen MB; Gandrup P; Laurberg S; Nilsson J; Kerstens R; De Pauw M
Scand J Gastroenterol; 2002 Apr; 37(4):431-6. PubMed ID: 11989834
[TBL] [Abstract][Full Text] [Related]
9. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans.
Bouras EP; Camilleri M; Burton DD; McKinzie S
Gut; 1999 May; 44(5):682-6. PubMed ID: 10205205
[TBL] [Abstract][Full Text] [Related]
10. Prucalopride.
Frampton JE
Drugs; 2009; 69(17):2463-76. PubMed ID: 19911858
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study.
Quigley EM; Vandeplassche L; Kerstens R; Ausma J
Aliment Pharmacol Ther; 2009 Feb; 29(3):315-28. PubMed ID: 19035970
[TBL] [Abstract][Full Text] [Related]
12. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives.
Tack J; van Outryve M; Beyens G; Kerstens R; Vandeplassche L
Gut; 2009 Mar; 58(3):357-65. PubMed ID: 18987031
[TBL] [Abstract][Full Text] [Related]
13. A placebo-controlled trial of prucalopride for severe chronic constipation.
Camilleri M; Kerstens R; Rykx A; Vandeplassche L
N Engl J Med; 2008 May; 358(22):2344-54. PubMed ID: 18509121
[TBL] [Abstract][Full Text] [Related]
14. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers.
Poen AC; Felt-Bersma RJ; Van Dongen PA; Meuwissen SG
Aliment Pharmacol Ther; 1999 Nov; 13(11):1493-7. PubMed ID: 10571606
[TBL] [Abstract][Full Text] [Related]
15. The association between prucalopride efficacy and constipation type.
Jadav AM; McMullin CM; Smith J; Chapple K; Brown SR
Tech Coloproctol; 2013 Oct; 17(5):555-9. PubMed ID: 23703575
[TBL] [Abstract][Full Text] [Related]
16. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
[TBL] [Abstract][Full Text] [Related]
17. Effect of prucalopride on symptoms of chronic constipation.
Tack J; Stanghellini V; Dubois D; Joseph A; Vandeplassche L; Kerstens R
Neurogastroenterol Motil; 2014 Jan; 26(1):21-7. PubMed ID: 24106924
[TBL] [Abstract][Full Text] [Related]
18. Prucalopride for chronic constipation.
Lacy BE; Loew B; Crowell MD
Drugs Today (Barc); 2009 Dec; 45(12):843-53. PubMed ID: 20135019
[TBL] [Abstract][Full Text] [Related]
19. Prucalopride: a review of its use in the management of chronic constipation.
Keating GM
Drugs; 2013 Nov; 73(17):1935-50. PubMed ID: 24194435
[TBL] [Abstract][Full Text] [Related]
20. Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial.
Foxx-Orenstein AE; Camilleri M; Szarka LA; McKinzie S; Burton D; Thomforde G; Baxter K; Zinsmeister AR
Neurogastroenterol Motil; 2007 Oct; 19(10):821-30. PubMed ID: 17539894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
